文献速递肝病消化道肿瘤与早癌

高龄而非合并症与肝细胞癌患者更差生存相关

Older Age But Not Comorbidity Is Associated With Worse Survival in Patients With Hepatocellular Carcinoma.
PubMed 文献 · Clin Gastroenterol Hepatol · 2024-11-20

这项回顾性队列研究纳入2002例肝细胞癌(HCC)患者,评估高龄(≥65岁)与合并症负担(Charlson合并症指数)与早期表现、接受根治性治疗及总生存的关联。调整分析显示,接受根治性治疗与较高合并症相关而非高龄;总生存与高龄显著相关(HR 1.25;95%CI 1.06-1.47)而与高合并症无关(HR 0.92;95%CI 0.77-1.09)。在早期HCC和接受根治性治疗的患者中,高龄仍与更差生存相关。

要点

  • 高龄(≥65岁)与HCC患者更差总生存相关(HR 1.25;95%CI 1.06-1.47)。
  • 高合并症负担与总生存无显著关联(HR 0.92;95%CI 0.77-1.09)。
  • 早期HCC中高龄仍与更差生存相关(HR 1.99;95%CI 1.45-2.73)。

核心结论

  • 高龄而非合并症负担与更差生存相关,包括早期HCC患者;需进一步研究以明确合并症在HCC预后中的作用。

研究设计与样本

  • 回顾性队列研究,纳入2010年1月至2023年2月在两个健康系统诊断的2002例HCC患者(中位年龄61岁;76%男性;21%早期)。

主要发现

  • 调整分析中,接受根治性治疗与较高合并症相关而与高龄无关。
  • 总生存与高龄显著相关(HR 1.25;95%CI 1.06-1.47),与高合并症无关(HR 0.92;95%CI 0.77-1.09)。
  • 早期HCC患者中高龄与更差生存相关(HR 1.99;95%CI 1.45-2.73)。
  • 接受根治性治疗患者中高龄与更差生存相关(HR 1.52;95%CI 1.10-2.10)。
  • 中位生存:年轻 vs 高龄总体20 vs 14个月,早期HCC 65 vs 49个月,接受根治性治疗者113 vs 60个月。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Age and comorbidity are key factors in assessing patient prognosis and informing stopping rules for cancer screening eligibility, but their impact has not been rigorously evaluated in patients with hepatocellular carcinoma (HCC). METHODS: We conducted a retrospective cohort study of patients diagnosed with HCC at 2 health systems between January 2010 and February 2023. We used multivariable logistic regression and Cox proportional hazards models to evaluate the associations between older age (≥65 years) and comorbidity burden (Charlson Comorbidity Index) with early-stage presentation, curative treatment receipt, and overall survival. We performed subgroup analyses in patients with early-stage HCC. RESULTS: We identified 2002 patients with HCC (median age, 61 years; 76% male; 21% early-stage), with a median survival of 15.7 months. In adjusted analyses, curative treatment receipt was associated with higher comorbidity but not older age. Conversely, overall survival was significantly associated with older age (hazard ratio [HR], 1.25; 95% confidence interval [CI], 1.06-1.47) but not high comorbidity (HR, 0.92; 95% CI, 0.77-1.09). Older age continued to be associated with worse survival among patients with early-stage HCC (HR, 1.99; 95% CI, 1.45-2.73) and those who underwent curative treatment (HR, 1.52; 95% CI, 1.10-2.10). Median survival for younger versus older individuals was 20 versus 14 months overall, 65 versus 49 months for patients with early-stage HCC, and 113 versus 60 months for those with curative treatment. CONCLUSIONS: Older age but not comorbidity burden is associated with worse survival, including among patients with early-stage HCC. Further studies are needed to define the role of comorbidity in HCC prognostication.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Kanneganti M, Al-Hasan M, Bourque S, et al. Older Age But Not Comorbidity Is Associated With Worse Survival in Patients With Hepatocellular Carcinoma. Clin Gastroenterol Hepatol. 2024. PMID: 39571877. doi:10.1016/j.cgh.2024.10.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。